Failure of Current Antibiotic First-line Regimens and Mortality in Hospitalized Patients with Spontaneous Bacterial Peritonitis

Overview

Journal Infection

Date 2009 Jan 27

PMID 19169633

Citations 40

Authors

A Umgelter

W Reindl

M Miedaner

R M Schmid

W Huber

Affiliations

Soon will be listed here.

Abstract

Background: Increases in Gram-positive infections and infections with Enterobacteriaceae with antimicrobial resistance have been reported in patients with spontaneous bacterial peritonitis (SBP). This study was performed to investigate the rate of treatment failures of recommended empirical therapies and the impact on mortality.

Patients And Methods: A prospectively collected database comprising 101 patients with SBP (70 nosocomial, 31 community acquired) treated at a university hospital between 2002 and 2006 in Munich, Germany, was analyzed.

Results: 17 patients initially received a broader than recommended antibiotic regimen. Most of these were treated in the intensive care unit because of severe sepsis/septic shock. Hospital mortality in this group was 82%. A modification of therapy was necessary in 24 of the 84 patients receiving one of the published first-line therapies (cefotaxime, ampicillin/clavulanate, or ciprofloxacin). Mortality was significantly higher in these patients than in those with no change in treatment (66.7% vs 30%, p = 0.002). In 29 patients with positive cultures, mortality was also higher in those with an ineffective first-line treatment (90% vs 45%, p = 0.032). In the multivariable analysis, a modification of antibiotic treatment was an independent risk factor for mortality (odds ratio 5.876, 95% confidence interval 1.826-18.910, p = 0.003). In 41 culture-positive cases, the most commonly cultured pathogens were Escherichia coli (n = 17) and Enterococcus faecium (n = 10). Of the encountered bacterial microorganisms, 14 (33.3%) were resistant to cefotaxime, 17 (38.6%) were resistant to amoxicillin/clavulanate, and 19 (45.2%) were resistant to ciprofloxacin. 29 (64.4%) of the isolates were resistant to one of the recommended firstline antibiotic regimens, and 11 (24.4%) of the isolates were resistant to all three.

Conclusion: Recommended empirical antibiotic regimens fail to achieve the desired effect in a substantial number of hospitalized patients with SBP. This has a negative impact on mortality.

Citing Articles

Ghomari K, Saddari A, Abdessalami O, Benmoussa C, Belmahi S, Zrouri H Tunis Med. 2025; 103(1):130-134.

PMID: 39812206 PMC: 11906237. DOI: 10.62438/tunismed.v103i1.5412.

Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Shift in the Microbial Pattern? A Retrospective Analysis.

Pimentel R, Leitao J, Gregorio C, Santos L, Carvalho A, Figueiredo P GE Port J Gastroenterol. 2022; 29(4):256-266.

PMID: 35979243 PMC: 9274822. DOI: 10.1159/000518585.

as a causative agent of spontaneous bacterial peritonitis.

Barry K, Finn A BMJ Case Rep. 2022; 15(4).

PMID: 35459657 PMC: 9036354. DOI: 10.1136/bcr-2022-249550.

Predictors of Short-Term Mortality Following First Episode of Spontaneous Bacterial Peritonitis in Hospitalized Cirrhotic Patients.

Elzouki A, Hamad A, Almasri H, Ata M, Ashour A, Othman M Cureus. 2021; 13(10):e18999.

PMID: 34853741 PMC: 8609112. DOI: 10.7759/cureus.18999.

Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany.

Hillert A, Schultalbers M, Tergast T, Vonberg R, Rademacher J, Wedemeyer H BMC Gastroenterol. 2021; 21(1):296.

PMID: 34284732 PMC: 8290615. DOI: 10.1186/s12876-021-01871-w.

References

Cholongitas E, Senzolo M, Patch D, Kwong K, Nikolopoulou V, Leandro G . Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther. 2006; 23(7):883-93. DOI: 10.1111/j.1365-2036.2006.02842.x. View

Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Castells L . Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999; 341(6):403-9. DOI: 10.1056/NEJM199908053410603. View

Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V . Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002; 35(1):140-8. DOI: 10.1053/jhep.2002.30082. View

Alvarez-Lerma F . Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 1996; 22(5):387-94. DOI: 10.1007/BF01712153. View

Singh N, Wagener M, Gayowski T . Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit. Clin Microbiol Infect. 2003; 9(6):531-7. DOI: 10.1046/j.1469-0691.2003.00691.x. View

Rello J, Gallego M, Mariscal D, Sonora R, Valles J . The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med. 1997; 156(1):196-200. DOI: 10.1164/ajrccm.156.1.9607030. View

Dellinger R, Carlet J, Masur H, Gerlach H, Calandra T, Cohen J . Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004; 32(3):858-73. DOI: 10.1097/01.ccm.0000117317.18092.e4. View

Grange J, Amiot X, Grange V, Gutmann L, Biour M, Bodin F . Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. Hepatology. 1990; 11(3):360-4. DOI: 10.1002/hep.1840110305. View

Kollef M, Sherman G, Ward S, Fraser V . Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999; 115(2):462-74. DOI: 10.1378/chest.115.2.462. View

10.

Pedersen G, Schonheyder H, Steffensen F, Sorensen H . Risk of resistance related to antibiotic use before admission in patients with community-acquired bacteraemia. J Antimicrob Chemother. 1999; 43(1):119-26. DOI: 10.1093/jac/43.1.119. View

11.

Ricart E, Soriano G, Novella M, Ortiz J, Sabat M, Kolle L . Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol. 2000; 32(4):596-602. DOI: 10.1016/s0168-8278(00)80221-4. View

12.

Scarsi K, Feinglass J, Scheetz M, Postelnick M, Bolon M, Noskin G . Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay. Antimicrob Agents Chemother. 2006; 50(10):3355-60. PMC: 1610056. DOI: 10.1128/AAC.00466-06. View

13.

Rimola A, Garcia-Tsao G, Navasa M, Piddock L, Planas R, Bernard B . Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000; 32(1):142-53. DOI: 10.1016/s0168-8278(00)80201-9. View

14.

MacArthur R, Miller M, Albertson T, Panacek E, Johnson D, Teoh L . Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis. 2003; 38(2):284-8. DOI: 10.1086/379825. View

15.

Campillo B, Richardet J, Kheo T, Dupeyron C . Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis. 2002; 35(1):1-10. DOI: 10.1086/340617. View

16.

Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik S . The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998; 244(5):379-86. DOI: 10.1046/j.1365-2796.1998.00379.x. View

17.

Luna C, Vujacich P, Niederman M, Vay C, Gherardi C, Matera J . Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997; 111(3):676-85. DOI: 10.1378/chest.111.3.676. View

18.

Terg R, Cobas S, Fassio E, Landeira G, Rios B, Vasen W . Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. J Hepatol. 2000; 33(4):564-9. DOI: 10.1034/j.1600-0641.2000.033004564.x. View

19.

Mercader J, Gomez J, Ruiz J, Garre M, Valdes M . Use of ceftriaxone in the treatment of bacterial infections in cirrhotic patients. Chemotherapy. 1989; 35 Suppl 2:23-6. DOI: 10.1159/000238735. View

20.

Felisart J, Rimola A, Arroyo V, Quintero E, Gines P, Rodes J . Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology. 1985; 5(3):457-62. DOI: 10.1002/hep.1840050319. View